Skinvisible, Inc. (SKVI)
| Market Cap | 276.93K |
| Revenue (ttm) | 20,000 |
| Net Income (ttm) | -5.15M |
| Shares Out | 4.54M |
| EPS (ttm) | -1.13 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 562 |
| Open | 0.0610 |
| Previous Close | 0.0610 |
| Day's Range | 0.0610 - 0.0610 |
| 52-Week Range | 0.0550 - 0.1399 |
| Beta | -0.39 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About SKVI
Skinvisible, Inc., together with its subsidiaries, focuses on the development, manufacture, and sale of topical, transdermal, and mucosal polymer-based delivery system technologies and formulations for use in pharmaceutical, over the counter, personal skincare, and cosmetic arenas. Its non-dermatological formulations offer solutions for women's health, pain management, and other markets. The company offers sunless tanning and sunscreen products. It also licenses to pharmaceutical companies; assists pharmaceutical clients in the early developmen... [Read more]
Financial Performance
In 2023, Skinvisible's revenue was $20,000, a decrease of -92.84% compared to the previous year's $279,296. Losses were -$2.38 million, 7.74% more than in 2022.
Financial StatementsNews
Skinvisible Announces Significant Progress in Licensee's Clinical Trials for Invisicare Formulation Targeting Nethertons Syndrome
LAS VEGAS, NV / ACCESSWIRE / February 14, 2024 / Skinvisible, Inc. ("Skinvisible") (OTCQB:SKVI) is excited to share a promising update on the ongoing clinical trials conducted by its licensee, Quoin P...
Skinvisible Announces First Invisicare Delivery Technology Product to Receive U.S. FDA Acceptance of Investigational New Drug
LAS VEGAS, NV / ACCESSWIRE / June 6, 2022 / Skinvisible, Inc. ("Skinvisible") (OTCQB:SKVI), is pleased to announce that its licensee Quoin Pharmaceuticals, Inc. ("Quoin") (NASDAQ:QNRX), has received U...